Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
In: Lancet, Jg. 373 (2009-06-06), Heft 9679, S. 1949-1957
Online
academicJournal
Zugriff:
The article discusses a study which examined the efficacy, safety and immunogenicity of the quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 virus-like-particle vaccine in women with age 24-45 years. Women in these age groups with no history of genital warts or cervical disease from community and academic health centres and primary health-care providers were enrolled in a placebo-controlled, double-blind study and were administered with the HPV vaccine. The study reported no vaccine-related serious adverse events after the administration.
| Titel: |
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
|
|---|---|
| Autor/in / Beteiligte Person: | Muñoz, Nubia ; Manalastas Jr., Ricardo ; Pitisuttihum, Punee ; Tresukosol, Damrong ; Monsonego, Joseph ; Ault, Kevin ; Clavel, Christine ; Luna, Joaquin ; Myers, Evan ; Hood, Sara ; Bautista, Oliver ; Bryan, Janine ; Taddeo, Frank J. ; Esser, Mark T. ; Vuocolo, Scott ; Haupt, Richard M. ; Barr, Eliav ; Saah, Alfred |
| Link: | |
| Zeitschrift: | Lancet, Jg. 373 (2009-06-06), Heft 9679, S. 1949-1957 |
| Veröffentlichung: | 2009 |
| Medientyp: | academicJournal |
| ISSN: | 0140-6736 (print) |
| DOI: | 10.1016/s0140-6736(09)60691-7 |
| Schlagwort: |
|
| Sonstiges: |
|